Heart failure in the diabetic patient.
This review examines the extent of the increased rate of heart failure (HF) in the diabetic patient, along with the possible causes for this increase and the poor prognosis associated with HF. Also reviewed are the therapies that are available for the treatment of diabetic HF and whether intensifying the use of these therapies might improve the worsened clinical outcomes for the patient who has diabetes.
Bell
David S H
DS
University of Alabama Medical School, Birmingham, AL, USA. dshbell@yahoo.com
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D001341:Autonomic Nervous System / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology; D003930:Diabetic Retinopathy / Q000453:epidemiology / Q000503:physiopathology; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000453:epidemiology* / Q000503:physiopathology; D006801:Humans; D006943:Hyperglycemia / Q000453:epidemiology / Q000503:physiopathology; D006949:Hyperlipidemias / Q000453:epidemiology / Q000503:physiopathology; D007333:Insulin Resistance / Q000502:physiology; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D011379:Prognosis; D012084:Renin-Angiotensin System / Q000235:genetics / Q000502:physiology; D013318:Stroke Volume; D045162:Thiazolidinediones / Q000494:pharmacology / Q000627:therapeutic use; D018487:Ventricular Dysfunction, Left / Q000453:epidemiology / Q000503:physiopathology
D000319:Adrenergic beta-Antagonists; D000451:Mineralocorticoid Receptor Antagonists; D045162:Thiazolidinediones